// App-Quantinova.ai

5062 : A phase I dose-escalation trial of AEZS-108 in taxane- and castration-resistant prostate cancer (CRPC).

Researchers

Presenter

  • Jacek K. Pinski

Principal Investigators

  • Andrew V. Schally

  • Denice D Tsao-Wei

  • Tanya B. Dorff

  • Susan G. Groshen

  • Shigang Xiong

  • David I. Quinn

  • Yu-Chong Tai

  • Juergen Engel

  • Stephen V. Liu

Medical Centers

  • Aeterna Zentaris, Quebec, QC, Canada

  • University of Miami Miller School of Medicine, Miami, FL

  • California Institute of Technology, Pasadena, CA.

  • University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Circulating tumor cells

  • Prostate specific antigen

Drug/Treatment

  • Zoptarelin doxorubicin

  • taxane

  • LHRH

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01240629

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved